Modulation of neuronal nkcc1 as a therapeutic strategy for spasticity and related disorders
US-2024416127-A1 · Dec 19, 2024 · US
Inhibition of c-Myc ubiquitination to prevent cancer initiation and progression
US9241920B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9241920-B2 |
| Application number | US-201214354822-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 29, 2012 |
| Priority date | Oct 27, 2011 |
| Publication date | Jan 26, 2016 |
| Grant date | Jan 26, 2016 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The present invention is directed to methods of inhibiting cancer cell proliferation, differentiation and/or survival. These methods involve the administration of Fbw7 E3 ligase inhibitors to inhibit c-Myc ubiquitination in cancerous cell populations, such as leukemic initiating cell populations, that are responsible for disease initiation and progression.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of inhibiting proliferation of leukemia cells said method comprising: administering to a population of leukemia cells a Fbw7 inhibitor, wherein the Fbw7 inhibitor is 1-(2-carboxynaphth-lyl)-2-naphthoic acid (SCF-12), in an amount. 2. The method of claim 1 , wherein the population of leukemic cells are selected from the group consisting of chronic myeloid leukemia cells, acute myeloid leukemia cells, and B-cell acute lymphoblastic leukemia cells. 3. The method of claim 1 , wherein the population of leukemia cells comprise a population of leukemic initiating cells. 4. The method of claim 3 , wherein the population of leukemic initiating cells comprises a population of BCR-ABL + CD34 + CD38 − cells. 5. The method of claim 1 , wherein said administering is in vivo. 6. The method according to claim 1 , wherein said administering is carried out in combination with another leukemia therapeutic. 7. The method according to claim 6 , wherein the leukemia therapeutic comprises a tyrosine kinase inhibitor. 8. The method according to claim 7 , wherein the tyrosine kinase inhibitor is selected from the group consisting of imatinib mesylate, nilotinib, and dasatinib. 9. The method according to claim 6 , wherein the leukemia therapeutic is selected from the group consisting of a chemotherapeutic agent, radiation, an anti-angiogenic agent, an immune-enhancing agent, and combinations thereof. 10. The method according to claim 9 , wherein the leukemia therapeutic is a chemotherapeutic agent selected from the group consisting of cytarabine, cyclophosphamide, vincristine, prednisone, daunorubicin, PEG asparaginase, methotrexate, and leucovorin.
Assignees
Inventors
Classifications
Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title
Antineoplastic agents · CPC title
not condensed and containing further heterocyclic rings · CPC title
- A61K31/196Primary
the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil · CPC title
specific for leukemia · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9241920B2 cover?
- The present invention is directed to methods of inhibiting cancer cell proliferation, differentiation and/or survival. These methods involve the administration of Fbw7 E3 ligase inhibitors to inhibit c-Myc ubiquitination in cancerous cell populations, such as leukemic initiating cell populations, that are responsible for disease initiation and progression.
- Who is the assignee on this patent?
- Aifantis Iannis, Reavie Linsey, Buckley Shannon, and 1 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/196. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Jan 26 2016 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).